SK bioscience announced on March 21 that it has shipped about 440,000 doses of cell-cultured influenza vaccine SKY Cellflu from Andong L-House to its Thai partner Biogenetech. SKY Cellflu is a vaccine of SK bioscience’s own development. The vaccine supplied this time is a strain for flu predicted fo
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company has shipped approximately 440,000 doses of SKYCellflu to Biogenetech in Thailand from its vaccine manufacturing facility ‘L HOUSE’ in Andong, S
Samsung Bioepis is said to be reviewing the acquisition of the biosimilar business unit of U.S. biotech firm Biogen.According to the biotech industry on Aug. 2, Samsung Bioepis is considering acquiring Biogen’s biosimilar business unit, which has recently been put up for sale.Biogen has been a colla
Samsung Biologics has been embroiled in another patent infringement lawsuit. On Jan. 16, US pharmaceutical company Regeneron filed a patent infringement and prevention claim against Samsung Biologics and its subsidiary Samsung Bioepis in Seoul Central District Court in Korea.Regeneron claims that a
Samsung Electronics Chairman Lee Jae-yong met with global CEOs of big pharmaceutical companies and bio-venture startup incubation companies in the eastern United States, the world’s largest bio-cluster, to lay the groundwork for the success of Samsung’s biotech business.According to Samsung Electron
The Seoul Southern District Prosecutors' Office is investigating cryptocurrency exchange Bithumb.According to industry sources, the investigation has to do with market manipulation allegations and the investigation targets include domestic cryptocurrencies such as GOM2 and PXL.On Jan. 25, the pr
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. In 2022, healthcare stocks have been performing sluggishly in the NY stock market, affected by drastic absorption of market liquidity since early-2022. Given that 10-yr discounted cash flow is the mo
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed. Maintain BUY, target price of KRW1,200,000 We maintain BUY and TP of KRW1,200,000 on Samsung Biologics. Our investment highlights are (1) 3Q22 earnings beat, (2) secured growth drivers via the recent start of
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed. Maintain BUY; cut target price to KRW1.18mn We cut our TP (KRW1.24mn→KRW1.18mn) to reflect recent earnings and our slight downward revision to Samsung Bioepis earnings outlook, but we maintain BUY given that:(
Samsung Biologics’ market capitalization has surpassed that of Lonza, the world’s largest biopharmaceutical contract manufacturing organization (CMO) company.Samsung Biologics’ market cap stood at 59.43 trillion won as of April 28, exceeding the 42.85 billion Swiss francs (about 55.62 trillion won)
Samsung Biologics announced on April 20 that it has completed the purchase of Biogen’s stake in Samsung Bioepis for US$2.3 billion. With the completion of the first payment of US$1.0 billion pursuant to the terms of the acquisition agreement, Samsung Biologics has now fully acquired Samsung Bioepis
Samsung C&T and Samsung Electronics, major shareholders of Samsung Biologics, will jointly make a two-trillion-won equity investment in the biotech subsidiary.The two companies participated in Samsung Biologics' paid-in capital increase of 3.2 trillion won. Samsung Biologics is increasing its ca
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. In February, the m-m fall in major NYSE bio indices narrowed versus the January figures. We view overweighting within IBB on leading new drug companies such as Amgen and Vertex Pharma as being a sign
Jeil Pharmaceutical is stepping up efforts to develop new medicines. Onconic Therapeutics, a subsidiary specializing in new drug development, raised about 27.5 billion won through a capital increase in January and February to finance clinical trials of its new drug candidates.Jeil Pharmaceutical fou
The author is an analyst with NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. With higher global demand for biosimilars and healthy earnings at global leading bio CDMO players translating into accompanying share price hikes, we believe that the time is ripe for a need to
Samsung BioLogics will open a research and development (R&D) center for the contract development organization (CDO) business in San Francisco, the United States, in April, the company announced at the JP Morgan Healthcare Conference in San Francisco on Jan. 15 (local time).John Lim, vice president o
The 2020 JP Morgan Healthcare Conference, the world’s largest healthcare investment symposium for the pharmaceutical and biotech industry, opened in San Francisco, the United States, on Jan. 13 (local time), with some 1,500 pharma companies from 40 countries around the world participating. About 30
Samsung Bioepis said on April 25 (local time) that it has received final approval from the U.S. Food and Drug Administration (FDA) to sell its Enbrel biosimilar Eticovo (ingredient name: etanercept).Eticovo is the company’s third biosimilar product approved in the United States, following Renflexis
The global pharmaceutical industry was disappointed when U.S. pharmaceutical company Biogen announced on March 21 that it would stop the Phase 3 clinical trial of Alzheimer's disease (AD) treatment Aducanumab, which it has been co-developing with Japan's Eisai.The industry expected that Aduc
A South Korean court has suspended the first sanctions that the Securities and Futures Commission (SFC) under the Financial Services Commission (FSC) imposed on Samsung BioLogics Co. for a failure to disclose important information. Previously, the company obtained a court injunction to suspend the S